SOURCE: MYOS Corporation

MYOS Corporation

July 22, 2014 08:05 ET

MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects

Fortetropin ™ Significantly Increases Muscle Size and Lean Body Mass in Average Males With Modest Resistance Training

CEDAR KNOLLS, NJ--(Marketwired - July 22, 2014) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.

The University of Tampa clinical trial was designed to analyze important body composition measurements and strength performance at two dose levels of Fortetropin over a twelve week period. The randomized, double-blind, placebo controlled trial clinically demonstrated that Fortetropin resulted in statistically significant increases in both muscle size and lean body mass in average males. The study evaluated 45 male subjects adhering to a supervised nutritional intake program and a monitored modest resistance training regimen over a period of twelve weeks. The various endpoints included skeletal muscle hypertrophy, lean body mass, fat mass and measurements of strength and power. Subjects taking Fortetropin showed significantly improved lean body mass and increased muscle size compared to placebo.

Dr. Wilson commented, "The data from the study conducted in our human performance laboratory clearly demonstrates that Fortetropin resulted in significant muscle gains in recreationally trained individuals. Males taking daily supplements of Fortetropin and exercising twice per week showed impressive gains in muscle growth and lean body mass, which are both key components for overall health and longevity. I believe that more frequent resistance training supplemented by Fortetropin may potentially produce even greater gains in muscle health."

Robert Ashton, M.D., Chief Medical Officer of MYOS added, "We are very pleased with the results of this important clinical study. The University of Tampa trial data further supports use of Fortetropin in individuals who seek to build and retain healthy lean muscle. We believe this data will have major implications in age-management and may address an unmet need for treatment options in muscle disorders including age-associated muscle loss and in the management of muscle loss associated with many chronic illnesses."

Dr. Ashton continued, "Moving forward, we believe the daily use of Fortetropin in the broad population along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reducing inflammation."

MYOS plans to submit data from this clinical study for publication in a peer-reviewed journal and for presentation at a scientific medical conference.

About MYOS Corporation
MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit

The Company's first commercial product based on Fortetropin (MYO-T12®), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including,, and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information

  • MYOS Corporation Investor and Media Contact:
    Jenene Thomas
    Investor Relations and Corporate Communications
    (973) 509-0444
    Email contact